SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Laboratories declines on the BSE

18 Nov 2024 Evaluate

Dr. Reddy's Laboratories is currently trading at Rs. 1188.85, down by 37.20 points or 3.03% from its previous closing of Rs. 1226.05 on the BSE.

The scrip opened at Rs. 1195.60 and has touched a high and low of Rs. 1221.00 and Rs. 1171.00 respectively. So far 40061 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1420.20 on 21-Aug-2024 and a 52 week low of Rs. 1074.35 on 11-Dec-2023.

Last one week high and low of the scrip stood at Rs. 1299.45 and Rs. 1171.00 respectively. The current market cap of the company is Rs. 99166.63 crore.

The promoters holding in the company stood at 26.64%, while Institutions and Non-Institutions held 49.01% and 10.13% respectively.

Dr. Reddy's Laboratories’ US-based subsidiary -- Dr Reddy's Laboratories Inc is recalling 2,040 bottles of 15 mg Morphine Sulfate extended-release tablets due to ‘Failed Impurities/Degradation Specification’. It is also recalling another 532 100-count bottles of the medication in 30 mg strength for the same reason.

Dr Reddy's initiated the Class II nationwide recall on October 22 this year.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1315.85 -17.20 (-1.29%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×